The mission of the Division of Hematology is to be the premier institute for clinical and translational research in hematologic malignancies. Our focus is to improve the diagnosis and treatment of hematologic diseases. Physicians and scientists with special interest in certain diseases work together as a team which we referred to as a disease-oriented group (DOG). Each member of the team brings a particular expertise to the group. Each group consists of basic scientists, clinicians, and those interested in translational research. This research is carried out at all three sites of the Mayo Clinic enterprise — Rochester, Minnesota; Phoenix, Arizona; and Jacksonville, Florida. The Hematologic Malignancies Program is a funded program in the Mayo Clinic Cancer Center. The program also has SPORE (specialized program of research excellence) grants from the National Cancer Institute in lymphoma and myeloma as well as a Program Project Grant in multiple myeloma. Many investigators' research is funded by the National Institutes of Health and the National Cancer Institute and also from foundations. The Hematologic Malignancies Program has a very active clinical trials program which enrolls over 600 patients each year in clinical trials of new agents for patients with cancer. The group receives support from the Mayo Foundation including gifts from benefactors, patients, and families.
Investigators in the Hematologic Malignancies Program have been very active in the area of publications. For example, in 2008, the group published 260 manuscripts in peer-reviewed journals. Mayo Clinic hematologists also play a key role in national cooperative groups such as the North Central Cancer Treatment Group and the Eastern Cooperative Oncology Group.